40 GUEST STREET, BOSTON, MA
Reports First Quarter 2026 Financial Results and Recent Strategic Developments
Expands Pipeline with Exclusive License for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
Material disclosure
Stockholders Elect Pasha Sarraf to Cue Biopharma Board of Directors
Other Events
Lucinda Warren Appointed Interim CEO; Usman Azam Resigns
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Q1
FY 2025
Q3
Q2
FY 2024
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence